BRIEF published on 08/29/2024 at 18:05, 9 days 7 hours ago ABIVAX: Status of shares and voting rights as of July 31, 2024 Euronext Paris Voting Rights Actions Abivax Regulatory
BRIEF published on 08/29/2024 at 18:05, 9 days 7 hours ago ABIVAX : État des actions et des droits de vote au 31 juillet 2024 Euronext Paris Droits De Vote Actions Abivax Réglementaire
PRESS RELEASE published on 08/29/2024 at 18:00, 9 days 7 hours ago ABIVAX: Nombre d’actions composant le capital social et nombre total de droits de vote au 31.07.24. ABIVAX annonce le nombre d'actions et de droits de vote au 31.07.24, conformément aux réglementations en vigueur Euronext Paris Droits De Vote Actions Abivax Règlement Général
BRIEF published on 08/06/2024 at 08:35, 1 month 1 day ago Abivax Reaches Key Milestone with Recruitment of 600 Patients for Phase 3 ABTECT Trial Patient Recruitment Abivax Obefazimod Ulcerative Colitis Clinical Test
BRIEF published on 08/06/2024 at 08:35, 1 month 1 day ago Abivax franchit une étape clé avec le recrutement de 600 patients pour l'essai de phase 3 ABTECT Abivax Obefazimod Rectocolite Hémorragique Essai Clinique Recrutement Patients
PRESS RELEASE published on 08/06/2024 at 08:30, 1 month 1 day ago Abivax franchit une étape clé avec le recrutement de 600 patients pour l'essai de phase 3 ABTECT Abivax franchit une étape clé avec le recrutement de 600 patients pour l'essai de phase 3 ABTECT, confirmant son avancement vers l'objectif de recrutement complet au premier trimestre 2025 Abivax Recrutement Essai Clinique Phase 3 ABTECT
PRESS RELEASE published on 08/06/2024 at 08:30, 1 month 1 day ago Abivax franchit une étape clé avec le recrutement de 600 patients pour l'essai de phase 3 ABTECT Abivax franchit une étape clé avec le recrutement de 600 patients pour l'essai de phase 3 ABTECT, confirmant l'évolution favorable du projet. La société réaffirme ses prévisions pour 2025 Abivax Recrutement Traitement Phase 3 ABTECT
PRESS RELEASE published on 08/06/2024 at 08:30, 1 month 1 day ago Abivax Announces ABTECT Phase 3 Trial Achieves Key Enrollment Milestone Abivax announces ABTECT Phase 3 Trial surpasses 600-patient enrollment milestone, on track for full enrollment by early Q1 2025. Trial trends align with previous observations Abivax Obefazimod Ulcerative Colitis ABTECT Phase 3 Trial Enrollment Milestone
BRIEF published on 07/23/2024 at 18:05, 1 month 15 days ago ABIVAX: Nombre d'actions et droits de vote au 30 juin 2024 Droits De Vote Euronext Actions AMF Abivax
BRIEF published on 07/23/2024 at 18:05, 1 month 15 days ago ABIVAX: Number of shares and voting rights as of June 30, 2024 Voting Rights Euronext Actions AMF Abivax
Published on 09/07/2024 at 01:30, 23 hours 52 minutes ago Quantum Biopharma Receives Nasdaq Notification of Regaining Compliance with Nasdaq's Minimum Bid Price Requirement and Completes Debt Settlements
Published on 09/07/2024 at 00:30, 1 day ago Cheech and Chong’s Global Holding Company Responds to California’s Proposed Emergency Hemp Ban
Published on 09/06/2024 at 23:15, 1 day 2 hours ago BluSky Carbon Announces Extension of Strategic Marketing Agreement
Published on 09/07/2024 at 14:00, 11 hours 21 minutes ago Litigation costs drive US liability claims by 57% over past decade, reveals Swiss Re Institute
Published on 09/06/2024 at 22:00, 1 day 3 hours ago Successful completion of preset purchase plan for the acquisition of Northern Data Group shares by CEO Aroosh Thillainathan
Published on 09/06/2024 at 18:45, 1 day 6 hours ago Molten Ventures Plc: POS-Transaction in Own Shares
Published on 09/06/2024 at 18:15, 1 day 7 hours ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 09/06/2024 at 17:56, 1 day 7 hours ago Funding Circle Plc: POS-Transaction in Own Shares
Published on 09/06/2024 at 18:00, 1 day 7 hours ago Declaration of voting rights at the end of August 2024